Priced at an accessible $99, the Fitbit Air is designed for those who seek simplicity without sacrificing functionality. Unlike its competitor, Whoop, which charges monthly fees for its services, Fitbit Air offers a one-time purchase that provides users with core health metrics right out of the box—no hidden costs, just straightforward tracking.

With a focus on passive tracking, this device will monitor sleep patterns, heart rate, heart rate variability (HRV), and daily activity seamlessly. It’s an intriguing proposition: wear it and forget about it while it quietly gathers data about your body’s rhythms. This approach could attract individuals who are overwhelmed by traditional fitness trackers’ constant notifications and screens.

The Fitbit Air will be available in three appealing colors—Obsidian, Lavender, and Berry—and will offer four different band options: Performance Loop, Active Band, Elevated SoftFlex Band, and Metal Mesh Band. Each band caters to various lifestyles and preferences; for instance, the Active Band will come in both small and large sizes to ensure a comfortable fit for all users. Customization is apparently a big focus—yet it remains unclear which specific band will be included with the device upon purchase.

As Google ventures deeper into this competitive landscape, it’s clear they’re not just competing with the Apple Watch anymore. The Fitbit Air positions itself directly against Whoop—a brand known for its subscription model and targeted audience of serious athletes. With its innovative features and straightforward pricing model, Fitbit aims to carve out a niche among casual users and fitness enthusiasts alike.

This shift towards screen-free technology reflects broader trends in consumer preferences. Many users are seeking less intrusive ways to monitor their health without being constantly tethered to their devices. In this context, the Fitbit Air could resonate well with those who want to maintain a healthy lifestyle while minimizing distractions.

As we await its launch date, anticipation builds around how well this device will perform in real-world scenarios. Will it truly deliver on its promises of effortless tracking? What insights will it provide that other devices do not? Details remain unconfirmed as we look forward to seeing how consumers respond to this new entry in the fitness tracker market.

The post Fitbit Air: The New Contender in Fitness Tracking appeared first on The Business News.

As the sun rose over Devanahalli, north Bengaluru, the canteen served its usual fare — steaming plates of fluffy idlis and crispy vadas. Yet, within hours, the atmosphere shifted from routine to chaos. Employees began to feel unwell; soon after, they were admitted to two private hospitals for treatment with intravenous fluids. Thankfully, no casualties have been reported among those affected, but the incident has sent ripples of concern throughout the community.

The investigation into this unsettling episode is ongoing. Health officials have initiated an inquiry into food preparation, storage, and hygiene practices at the canteen. Samples of leftover food have been dispatched for laboratory testing; results are eagerly awaited. This scrutiny comes amid broader concerns regarding fermented foods — particularly during the sweltering summer months when bacterial contamination risks escalate significantly.

Fermented foods like idli and dosa require meticulous care in warmer weather due to their susceptibility to spoilage. Experts note that such foods have a shorter shelf life when temperatures rise and humidity increases. If improperly handled or stored, they can quickly become breeding grounds for harmful bacteria — a fact that has now gained alarming relevance in light of this incident.

The implications of this event extend beyond individual health concerns; it shines a spotlight on food safety protocols across Bengaluru. The city is home to numerous canteens catering to thousands of employees daily. The recent outbreak serves as a wake-up call for both businesses and health authorities to reevaluate their practices and ensure stringent adherence to safety regulations.

Even as investigations continue, there is uncertainty surrounding what specific factors led to this outbreak. Details remain unconfirmed regarding whether it was a lapse in hygiene or an issue with ingredient sourcing that precipitated this crisis. What is clear is that vigilance must be heightened — not just in the corporate canteen where this incident occurred but across all establishments serving food.

As Bengaluru grapples with this unsettling reality, one thing remains certain: the health and well-being of its workforce depend on unwavering commitment to food safety standards. With results from laboratory tests pending and investigations underway, the community awaits answers that could prevent future incidents and restore confidence in their daily sustenance.

The post Bengaluru Canteen Food Poisoning: A Disturbing Incident appeared first on The Business News.

The employee, undeterred by the initial rejection, sought medical attention and obtained a doctor’s certificate recommending two days of rest. Armed with this documentation, he applied for sick leave through the HR portal, which was subsequently approved. However, the saga did not end there. The manager, still unconvinced, refused to accept the HR-approved sick leave and demanded to see the prescription, a move that many have criticized as an overreach of authority.

Reactions to the manager’s behavior have been swift and severe, particularly on social media platforms like Reddit. Users expressed outrage, describing the manager’s actions as emblematic of toxic workplace norms that prioritize productivity over employee well-being. One Reddit user succinctly captured the sentiment, stating, “Choose health over donkeys. If sick leave is policy-backed and HR-approved, your manager has no business gatekeeping it.” This incident has ignited a broader conversation about the treatment of sick leave requests and the rights of employees in the face of managerial scrutiny.

The issue is not isolated to this one incident. In India, the stigma surrounding sick leave is pervasive, with many employees feeling pressured to work through illness rather than risk being viewed as uncommitted. This cultural backdrop is compounded by alarming statistics: more than 2.4 billion workers globally are exposed to excessive heat, leading to over 22.85 million occupational injuries each year. In India, projections indicate that the country could lose about 5.8% of working hours by 2030 due to heat stress, a significant increase from 4.3% in 1995.

In 2023 alone, extreme heat cost India an estimated 181 billion potential labour hours, translating into income losses of about Rs 13 lakh crore (approximately $141 billion). These figures underscore the urgent need for more compassionate and flexible sick leave policies that acknowledge the realities of health and wellness in the workplace.

Meanwhile, the situation is not unique to India. In Spain, public debate has intensified around how sick leave is verified, monitored, and limited to medical necessity. The country recorded 53.7 temporary disability cases per 1,000 workers in 2025, prompting discussions about the adequacy of existing policies and their enforcement. Longer wait times for diagnostics, rehabilitation, or specialist visits can extend leave durations, further complicating the landscape of employee health management.

As the conversation around sick leave continues to evolve, observers are calling for a reevaluation of workplace policies that prioritize employee health. The need for systemic change is evident, as both employees and employers navigate the complexities of health, productivity, and workplace culture. The hope is that incidents like the one involving the corporate employee will serve as a catalyst for change, prompting organizations to adopt more humane approaches to sick leave and employee wellness.

The post Sick leave: The Controversy Surrounding in India appeared first on The Business News.

“Together for health. Stand with science,” resonates as a clarion call for World Health Day 2026, set to unfold on April 7. This year’s theme emphasizes the critical role of scientific collaboration in safeguarding health, a message that echoes louder than ever in our interconnected world.

As the global community grapples with health challenges, the campaign aims to spotlight the One Health approach, which recognizes the interdependence of human, animal, and environmental health. The International One Health Summit will take place on the same day, bringing together experts and advocates to discuss innovative solutions.

In a significant gathering, nearly 800 scientific institutions from over 80 countries will converge for the inaugural Global Forum of WHO Collaborating Centres, running from April 7 to 9. This unprecedented assembly underscores the importance of unity in the face of global health threats.

“We call on governments, scientists, health workers, partners, and the public to stand with science to protect lives, rebuild trust, and secure a healthier future,” the organizers stated, urging collective action in the pursuit of health equity.

The campaign invites everyone to participate through social media, utilizing hashtags like #StandWithScience and #WorldHealthDay, fostering a global dialogue around health issues.

World Health Day, celebrated annually on April 7, serves as a reminder of the ongoing efforts needed to improve health outcomes worldwide. The events planned for 2026 are not just a celebration but a call to action for all stakeholders.

As the date approaches, anticipation builds around the discussions and collaborations that will emerge from these gatherings, with hopes of setting a new agenda for global health.

Details remain unconfirmed regarding specific outcomes from the summit and forum, but the commitment to scientific collaboration remains steadfast.

World Health Day 2026 promises to be a pivotal moment in the ongoing journey toward a healthier future for all, reinforcing the message that together, we can achieve more.

The post World Health Day 2026: Together for Health, Stand with Science appeared first on The Business News.

AIIMS Mangalagiri, a beacon of medical education and healthcare in Andhra Pradesh, has reached a significant milestone by conferring degrees on 49 MBBS graduates. This achievement highlights the institution’s rapid growth since its inception in 2018, when it welcomed its first batch of 50 students. Today, AIIMS Mangalagiri boasts a total of 748 MBBS students, with an annual intake of 125, reflecting the increasing demand for medical education in the region.

The graduation ceremony not only celebrated the accomplishments of the students but also underscored the institution’s commitment to enhancing healthcare services. AIIMS Mangalagiri has completed an impressive 31 lakh outpatient department (OPD) consultations, with a daily patient footfall of around 3,500 to 4,000. This remarkable statistic illustrates the hospital’s vital role in serving the healthcare needs of the community.

Union Minister of State for Health and Family Welfare, Anupriya Patel, emphasized the government’s dedication to the medical sector, stating, “The Union government under the leadership of Prime Minister Narendra Modi is giving utmost priority to the medical sector.” This commitment is evident in the various schemes introduced to safeguard the health needs of the underprivileged in the country.

In a further enhancement of its healthcare capabilities, AIIMS Mangalagiri has recently installed a state-of-the-art Nucleic Acid Amplification Testing (NAAT) system, the first of its kind among all AIIMS in South India. This advanced system, which cost approximately ₹1.73 crore, significantly improves the detection of viral infections such as HIV, Hepatitis B, and Hepatitis C.

Ahanthem Singh, a key figure in the implementation of the NAAT system, remarked, “The NAAT system enhances safety by significantly reducing the diagnostic window period.” This advancement not only bolsters the hospital’s diagnostic capabilities but also reinforces its commitment to providing timely and effective healthcare.

The installation of the NAAT system and the graduation of the MBBS students are pivotal developments for AIIMS Mangalagiri, positioning it as a leader in medical education and healthcare services in the region. Observers anticipate that these advancements will further enhance the institution’s reputation and attract more students and patients alike.

As AIIMS Mangalagiri continues to evolve, the focus remains on expanding its educational programs and healthcare services, ensuring that it meets the growing needs of the population it serves. The future looks promising for this institution, as it aims to contribute significantly to the medical landscape of India.

The post AIIMS Mangalagiri Celebrates Milestone with Graduation of 49 MBBS Students appeared first on The Business News.

The BA.3.2 variant, commonly referred to as the Cicada variant, has emerged as a notable descendant of the BA.3 omicron subvariant that first appeared in 2022. Identified in South Africa in November 2024, this variant has quickly spread to over 20 countries, including 25 states in the United States. As health authorities monitor its rise, understanding the symptoms associated with this variant becomes increasingly important.

One of the most striking features of the Cicada variant is its extensive genetic makeup, carrying approximately 70 to 75 mutations in its spike protein. This significant number of mutations has raised questions about the variant’s transmissibility and severity. However, current evidence suggests that BA.3.2 does not lead to more severe illness compared to earlier variants. Dr. Adolfo García-Sastre, a prominent figure in infectious disease research, stated, “There’s no evidence that BA.3.2 is causing more severe disease or hospitalizations in countries where it’s more widespread.”

Common symptoms associated with the Cicada variant include cough, fever or chills, sore throat, congestion, shortness of breath, loss of smell or taste, fatigue, headache, and gastrointestinal issues such as diarrhea or vomiting. These symptoms largely mirror those seen in previous COVID-19 strains, particularly the Omicron variants. Health experts emphasize that most cases remain mild to moderate, resembling flu-like illness, especially among vaccinated individuals. As one health expert noted, “Most cases remain mild and can be managed at home with rest and hydration.”

Despite the variant’s mutations, vaccines are expected to provide strong protection against severe disease, even if breakthrough infections occur. Health authorities continue to advocate for staying up to date with vaccinations and taking precautions in crowded settings, particularly as the variant spreads in densely populated areas. Observers are encouraged to remain vigilant as the situation evolves.

As the Cicada variant gains traction, health experts are closely monitoring its impact. Symptoms linked to this variant remain consistent with those of previous strains, with no new or unusual signs reported thus far. This consistency in symptoms may help in early identification and management of cases, which is crucial for controlling the spread of the variant.

However, there are concerns regarding the effectiveness of current COVID-19 vaccines against the Cicada variant due to its multiple mutations. While vaccines are still expected to provide a level of protection, some experts warn that their effectiveness may not be as robust as against earlier strains. This has led to renewed discussions about the importance of booster shots and ongoing vaccination efforts.

In summary, the emergence of the Cicada variant underscores the need for continued vigilance in the fight against COVID-19. With its rapid spread and familiar symptom profile, the public is urged to remain informed and proactive in protecting their health. As health authorities work to monitor and respond to this variant, the emphasis on vaccination and preventive measures remains critical.

The post Cicada COVID Variant Symptoms: What You Need to Know appeared first on The Business News.

The Kerala government has been advocating for the establishment of an All India Institute of Medical Sciences (AIIMS) for several years, highlighting the pressing healthcare needs of the state. Despite multiple proposals submitted over the years, the Union government has yet to approve the project, leaving many residents and officials frustrated.

In 2025, the Kerala government identified land in Kinalur, Kozhikode, specifically for the proposed AIIMS project. However, the absence of a timeline for approval from the Centre has raised concerns among local leaders and citizens alike.

Union Minister of State for Health and Family Welfare, Prataprao Jadhav, recently confirmed, “The proposal for establishing AIIMS in Kerala has not been approved.” This statement has only intensified the political discourse surrounding the issue, especially with state Assembly elections on the horizon.

The demand for an AIIMS in Kerala has become a significant political issue, with Congress MPs Kodikunnil Suresh and Adoor Prakash voicing their concerns over the delay. They argue that the lack of a premier medical institution in the state is detrimental to the healthcare system and exacerbates existing challenges.

Historically, the Union Health Ministry sought ‘in-principle’ approval from the Finance Ministry in 2019 for the establishment of AIIMS in Kerala, but progress has since stalled. In 2016, several potential locations for the institute were proposed, yet none have materialized into concrete action.

The situation is compounded by the fact that the absence of an AIIMS in Kerala is not just a healthcare issue but a political one, as it is closely linked to the state’s electoral dynamics. Observers note that the demand for improved healthcare facilities is likely to resonate with voters, making it a pivotal topic in the upcoming elections.

Details remain unconfirmed regarding the reasons for the delay in approval of the AIIMS proposal, leaving many to speculate about the Centre’s priorities and the future of healthcare in Kerala. The timeline for the approval or implementation of the AIIMS proposal remains unclear, further fueling uncertainty among stakeholders.

As the political landscape heats up, the fate of the AIIMS proposal in Kerala hangs in the balance, with many hoping for a breakthrough that could finally address the state’s healthcare needs.

The post AIIMS in Kerala: Proposal Stalled Amid Political Tensions appeared first on The Business News.

As India grapples with the ongoing challenges of the COVID-19 pandemic, a new variant, known as the Cicada variant, has emerged, stirring concern among health officials and the public alike. This variant, classified as BA.3.2 and part of the Omicron family, carries over 70 mutations compared to the original Wuhan strain, with more than 50 of these mutations located in the spike protein alone.

The Cicada variant was first identified in South Africa in November 2024, and since then, it has spread to at least 22 countries, raising alarms about its potential impact on global health. Symptoms associated with this variant include cough, extreme fatigue, runny nose, headache, sore throat, mild fever, muscle and joint pain, loss of taste or smell, night sweats, and rash.

Despite the extensive mutations, preliminary assessments indicate that the Cicada variant is not confirmed to cause more severe illness than previous variants. However, the uncertainty surrounding its transmissibility and potential to evade immunity from prior infections or vaccinations remains a pressing concern.

In the United States, the first confirmed case of the Cicada variant was reported in June 2025, and by January 2026, three patients had been confirmed, all of whom recovered. Dr. Robert Hopkins Jr. commented on the situation, stating, “It is possible we will see Cicada become the dominant strain in the U.S., but that is by no means certain.” This highlights the unpredictable nature of viral evolution and its implications for public health.

The CDC has emphasized the importance of monitoring the spread of the BA.3.2 variant, noting that it provides valuable insights into the potential for this new lineage of SARS-CoV-2 to evade existing immunity. As health officials in India and around the world continue to track the Cicada variant, the focus remains on understanding its behavior and impact.

Details remain unconfirmed regarding the real-world severity of illness caused by the Cicada variant, leaving many questions unanswered. The emergence of this variant underscores the need for ongoing vigilance and research as the global community continues to navigate the complexities of the pandemic.

The post Cicada COVID Variant in India: A New Challenge on the Horizon appeared first on The Business News.

Sun Pharmaceutical Industries Limited, a leader in the pharmaceutical sector, is dedicated to enhancing patient care in areas such as psoriasis, alopecia areata, and acne. At the 2026 AAD Annual Meeting held in Denver, Colorado, the company presented 14 abstracts, showcasing its commitment to advancing dermatology and immunology.

Among the highlights was ILUMYA, a drug aimed at treating moderate-to-severe plaque psoriasis and nail psoriasis. The presentation emphasized not only the clinical efficacy and safety of ILUMYA but also its performance over time in real-world settings.

Another significant development is LEQSELVI, which is utilized for the treatment of severe alopecia areata. This therapy represents a crucial advancement for patients struggling with this challenging condition.

Additionally, WINLEVI, indicated for acne vulgaris, was discussed in the context of combination therapies, showcasing its versatility in dermatological treatment.

However, not all news was positive. The Phase II FLASH study for Fibromun did not meet its primary endpoint for progression-free survival (PFS), raising questions about its future in the market.

On a brighter note, Nidlegy achieved a remarkable milestone, with complete pathological responses in 52.6% of patients in the Phase II ‘Duncan’ study. This achievement underscores the potential of Nidlegy in treating specific patient populations.

Furthermore, the GLIOSTELLA study in late-line glioblastoma has completed enrollment in the U.S., marking a significant step forward in research for this aggressive cancer.

In light of previous challenges, a new submission for Nidlegy is being prepared after the withdrawal of a prior Marketing Authorization Application in 2025. This proactive approach reflects Sun Pharma’s resilience and commitment to bringing innovative therapies to market.

Dr. Ahmad Naim, a key figure at Sun Pharma, stated, “The data we are presenting at AAD underscore our commitment to advancing dermatology and immunology through meaningful science – spanning not only clinical efficacy and safety, but also how these therapies perform over time and in real-world practice.”

As the industry watches closely, observers expect that these developments will pave the way for further advancements in dermatological treatments, enhancing patient care and outcomes in the years to come.

The post Sun Pharma Unveils Promising Developments at AAD Annual Meeting appeared first on The Business News.